KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

Recruiting now

Conditions studied: Solid Tumor, Advanced Solid Tumor, Metastatic Cancer

In brief

A national, prospective, multi-center, open-label, multi-cohort study comprised of a framework to screen patients for actionable targets and evaluation of molecular profiling guided therapy recommended by MTB based on genomic alterations using targeted and/or immunotherapies outside of the approved indications via local clinical practice (Tier 1 \& 2) and clinical trials (Tier 3)

Key facts

Study ID

NCT05525858

Run by

Seoul National University Bundang Hospital

People needed

1000

Starts

2022-09-28

Expected to finish

2027-03-01

Last updated by the study team

2026-06-22

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 19 years of age or older
• Histologically proven locally advanced or metastatic solid tumors*** who showed disease progression on standard first line anti-cancer treatment and/or has no standard treatment option
• ** very rare diseases without standard treatment option which form solid mass, such as Erdheim Chester disease can be enrolled after KOSMOS MTB approval
• A genomic test results must be available in a MFDS-accredited for laboratories offering service, or in part of clinical trial/study or other commercial labs approved and certified by regulatory bodies compatible with MFDS, such as CLIA. A genomic test can be conducted with tumor tissue as well as plasma circulating tumor DNA.
• Results from genomic profiling tests performed after diagnosis with metastatic/advanced disease to registration are acceptable. NGS results performed within three years prior to registration are preferred. Those patients with NGS results from primary tumor or more than 3 years prior to enrollment can be registered and whether NGS data is acceptable will be subject to MTB decision.
• NGS panels should be i. Tested in a lab that is accredited by one or more quality assurance program (e.g., Korean Institute of Genomic Testing Evaluation, The Korean Society of Pathologists, Korean Society for Laboratory Medicine, Korea Laboratory Accreditation Scheme, etc.) ii. Patients who have insufficient genomic information from their NGS results (e.g., lack of variant calling format file or uninterpretable reports) or who are candidates of immunotherapy will submit their tissue and/or blood, for central NGS testing and exploratory biomarker analysis.
• Ability to understand and the willingness to sign a written informed consent document
• Life expectancy of at least 12 weeks
• Adequate recovery from most recent systemic or local treatment for cancer.

You may not qualify if…

• Patients receiving any anti-cancer treatment (local treatment, chemotherapy, immunotherapy, targeted therapy) within 2 weeks prior to the start of study treatment
• Any clinical condition, according to the opinion of site physicians, which makes molecular profiling guided therapy not at the best interest of the participating patient.
• Patients who have ongoing toxicities of ≥ CTCAE 2, other than peripheral neuropathy, related to previous anti-cancer treatment. Patients with ongoing peripheral neuropathy of ≥ CTCAE 3 will be excluded. Laboratory abnormalities ≥ CTCAE 2 considered as not clinically significant by the study physician will be allowed.
• Pregnant or breastfeeding, or intending to become pregnant during the study

Where it is running

• Pusan National University Yangsan Hospital — Yangsan, South Korea (enrolling)
• Chungbuk National University Hospital — Chungju, South Korea (enrolling)
• Keimyung University Dongsan Hospital — Daegu, South Korea (enrolling)
• Kyungpook National University Chilgok Hospital — Daegu, South Korea (enrolling)
• Yeungnam University Medical Center — Daegu, South Korea (enrolling)
• Chungnam National University Hospital — Daejeon, South Korea (enrolling)
• National Cancer Center — Goyang, South Korea (enrolling)
• Chonnam National University Hwasun Hospital — Hwasun, South Korea (enrolling)
• Gachon University Gil Medical Center — Incheon, South Korea (enrolling)
• The Catholic University of Korea, Incheon St. Mary's Hospital — Incheon, South Korea (enrolling)
• Jeonbuk National University Hospital — Jeonju, South Korea (enrolling)
• Gyeongsang National University Hospital — Jinju, South Korea (enrolling)
• Dong-A University Hospital — Pusan, South Korea (enrolling)
• Cha University Bundang Medical Center — Seongnam, South Korea (enrolling)
• Seoul National University Bundang Hospital — Seongnam, South Korea (enrolling)
• Asan Medical Center — Seoul, South Korea (enrolling)
• Chung-ang University Hospital — Seoul, South Korea (enrolling)
• Ewha womans university Mokdong Hospital — Seoul, South Korea (enrolling)
• Gangbuk Samsung Hospital — Seoul, South Korea (enrolling)
• Ulsan University Hospital — Ulsan, South Korea (enrolling)
• Soonchunhyang University Hospital Bucheon — Bucheon-si, South Korea (enrolling)
• Korea University Anam Hospital — Seoul, South Korea (enrolling)
• Korea University Guro Hospital — Seoul, South Korea (enrolling)
• Samsung Medical Center — Seoul, South Korea (enrolling)
• Seoul National University Hospital — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.